PharmAbcine
PharmAbcine is a clinical-stage South Korean biotech developing fully human monoclonal antibodies for cancer and ophthalmology indications, pursuing a licensing-out model with global biopharmaceutical partners.
- Company typePublic
- Founded2008
- HeadquartersDaejeon, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What PharmAbcine does
PharmAbcine is a clinical-stage biotechnology company headquartered in Daejeon, South Korea, that develops fully human therapeutic monoclonal antibodies for cancer, vascular eye diseases, and vascular-related conditions. The company's pipeline is built on its proprietary HuPhage Display fully human antibody library, which enables discovery of differentiated biologics with novel mechanisms of action. Core clinical assets include Olinvacimab (a VEGFR2-neutralizing antibody in Phase 2 for metastatic triple-negative breast cancer in combination with pembrolizumab), PMC-309 (a first-in-class anti-VISTA immune checkpoint antibody in Phase 1a/b for advanced or metastatic solid tumors in Australia), and PMC-403 (a TIE2-activating antibody that completed Phase 1 for chronic wet AMD and holds FDA Orphan Drug Designation for Systemic Capillary Leak Syndrome). Additional pipeline assets include PMC-402 and preclinical PMC-005, an anti-EGFRviii antibody positioned for CAR-T, CAR-NK, and radioimmunotherapy modalities.
The company's business model is licensing-out: it advances novel antibody candidates through clinical and preclinical development and seeks global biopharmaceutical partners for late-stage development and commercialization. Strategic partners include MSD/Merck (clinical supply of Keytruda for combination trials and joint patent filing), Aprogen (out-licensee of PMC-309), Samsung Biologics (contract manufacturing), and Arontier Inc. (AI-driven antibody platform collaboration). PharmAbcine operates wholly-owned subsidiaries Wincal BioPharm in the United States, focused on an eye-drop delivery platform, and PharmAbcine Australia Pty, supporting clinical operations. The company is publicly listed on KOSDAQ under ticker 208340/203840, with 11–50 employees and no commercialized products; its revenue derives from licensing milestones, government grants (KDDF), and capital markets activity.
PharmAbcine firmographics
Firmographics- Name
- PharmAbcine
- Legal name
- PharmAbcine Inc.
- Website
- https://pharmabcine.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PharmAbcine is a clinical-stage South Korean biotech developing fully human monoclonal antibodies for cancer and ophthalmology indications, pursuing a licensing-out model with global biopharmaceutical partners.
- Ownership category
- akta.pro rank
Where PharmAbcine is headquartered
LocationHeadquarters
- HQ city
- Daejeon
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
PharmAbcine business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Licensing Revenue: PharmAbcine's primary business model is to develop novel antibody therapeutics and license them out to global biopharma companies. The company develops candidates through clinical stages and seeks licensing partnerships for commercialization.
- Out-licensed PMC-309 to Aprogen: PharmAbcine recently out-licensed PMC-309 to Aprogen (www.aprogen.com), representing a revenue-generating licensing transaction for their VISTA-targeting immune checkpoint inhibitor candidate.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
PharmAbcine product offering
Product offeringCore offering
PharmAbcine is a clinical-stage biotechnology company that discovers and develops fully human therapeutic monoclonal antibodies using its proprietary HuPhage Display platform, with a pipeline targeting cancer, inflammatory diseases, and ophthalmology indications. Its lead candidates include Olinvacimab (anti-VEGFR2), PMC-309 (anti-VISTA), PMC-403 (TIE2-activating), PMC-402, and PMC-005, developed either for direct clinical advancement or for out-licensing to global biopharmaceutical partners.
Product overview
PharmAbcine is a clinical-stage biotech company developing a portfolio of novel antibody therapeutics based on its proprietary HuPhage Display fully human antibody platform. The company focuses on three core clinical-stage assets: Olinvacimab (VEGFR2-neutralizing antibody in Phase 2 for mTNBC), PMC-309 (anti-VISTA antibody in Phase 1 for solid tumors), and PMC-403 (TIE2-activating antibody successfully completing Phase 1 for wet AMD). Additional pipeline products include PMC-402 and PMC-005 (anti-EGFRviii for CAR-T applications). Through its U.S. subsidiary Wincal BioPharm, the company is developing an eye-drop platform to replace intravitreal injections. The company leverages its AI-driven antibody development platform developed in partnership with Arontier.
Differentiator
Problem solved
Functional benefit
Products and services
- Olinvacimab (PMC-501) Anti-VEGFR2 fully human monoclonal antibody being developed for oncology indications; the company's lead clinical-stage asset, offered to biopharma partners for licensing and co-development.
- PMC-309 Anti-VISTA fully human monoclonal antibody candidate targeting the VISTA immune checkpoint for immuno-oncology applications; offered for licensing to global biopharmaceutical partners.
- PMC-403 TIE2-activating fully human monoclonal antibody candidate being developed for ophthalmology and vascular-related indications, with potential applications enabled by the company's non-ophthalmic eye-drop delivery technology.
- PMC-402 Early-stage pipeline antibody candidate discovered via PharmAbcine's HuPhage Display platform, in development for therapeutic applications.
- PMC-005 Early-stage pipeline antibody candidate discovered via PharmAbcine's HuPhage Display platform, in development for therapeutic applications.
- Wincal BioPharm non-ophthalmic eye-drop delivery platform Proprietary non-ophthalmic eye-drop antibody delivery technology operated through US subsidiary Wincal BioPharm, enabling topical ocular delivery of antibody therapeutics without intravitreal injection; offered to partners developing ophthalmology biologics.
Quantifiable outcome
- PMC-403 demonstrated favorable tolerability and predictable safety profile with no dose-limiting toxicities or major safety concerns in Phase 1 trial for chronic wet AMD patients
- +2 more outcomes
Companies that use PharmAbcine
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
PharmAbcine technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
PharmAbcine partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered strategic, minor and core.
- Arontier Inc.strategicPartnership to jointly develop an AI-based antibody innovation drug development platform, converging AI and antibody data to create a new paradigm for antibody-based drug discovery. Arontier brings strong foundation in AI-driven drug discovery.
- LegoChem BiosciencesminorResearch collaboration agreement for antibody-based drug development.
- FutureChemminorSigned MoU to explore possibilities of developing novel radiopharmaceuticals.
- Samsung BiologicscoreDevelopment and manufacturing partnership for oncology and neovascular treatment antibody therapeutics. Samsung Biologics provides contract development and manufacturing services for PharmAbcine's pipeline candidates including PMC-403.
- MSD (Merck)coreMSD provides Keytruda (pembrolizumab) free of charge for combination therapy trials with PharmAbcine's olinvacimab (for mTNBC) and PMC-309 (for solid tumors). MSD has been invited to the MSD@JPM Dinner Reception and extended clinical collaboration agreements.
- Dr. Kirk Druey (NIH)minorResearch collaboration with former Chief of NIH's Lung and Vascular Inflammation Section to explore PMC-403's efficacy in animal models for Idiopathic Systemic Capillary Leak Syndrome (SCLS/Clarkson disease).
- Wincal BioPharm (U.S. Subsidiary)coreU.S.-based subsidiary developing a new eye-drop platform intended to replace existing intravitreal injection therapies. Led by CSO TaeWeon Lee. Selected for oral presentation at ARVO 2024.
- Prof. Quan Dong Nguyen (Stanford University)minorProfessor at Stanford University School of Medicine who plays a key role in PharmAbcine's ophthalmology therapeutics division through Wincal BioPharm collaboration.
- BinexminorCMO (Contract Manufacturing Organization) contract with Binex to produce olinvacimab at its new 5,000L production line.
- WuXi Shuangliang Biotechnology (SLBio)minorResearch collaboration agreement to evaluate combination therapy to treat NSCLC (non-small cell lung cancer).
Scale indicators8 records
Recent moves6 records
Expansion highlights7 records
PharmAbcine competitors and assessment
Company assessmentBroad incumbents
- Genexine: Korean clinical-stage biotech developing novel biologics (including antibody and fusion protein platforms) for oncology and autoimmune indications. Comparable Korean biotech peer with similar clinical-stage profile and out-licensing orientation.
- Celltrion: Major Korean biologics company with a broad biosimilars and novel biologics portfolio. Operates at much larger scale with manufacturing infrastructure, serving as a benchmark for Korean antibody/biologics commercialization.
- Regeneron Pharmaceuticals: Global leader in therapeutic antibodies (Eylea, Dupixent, Libtayo IO franchise) using proprietary VelociSuite platforms. Broad incumbent in antibody therapeutics including anti-VEGF ophthalmology and oncology where PharmAbcine competes.
- Hanmi Pharmaceutical: Major South Korean pharmaceutical company with biologics and antibody pipeline targeting oncology, ophthalmology, and autoimmune indications. Larger incumbent operating broadly in adjacent therapeutic categories.
Others
- WuXi Biologics: Global biologics CDMO providing end-to-end antibody development and manufacturing services. Serves as a comparable ecosystem/development partner rather than a direct therapeutic competitor.
- Samsung Biologics: Global CDMO providing contract development and manufacturing services for PharmAbcine's antibody candidates. Operates as a service provider rather than competing product developer but is closely tied via manufacturing partnership.
Direct peers
- Genmab: Pioneering antibody therapeutics company with proprietary platforms (DuoBody bispecifics, Hexabody) and broad oncology partnerships with major pharma. Highly comparable as a technology-and-licensing-driven antibody developer targeting oncology.
- MacroGenics: US clinical-stage biotech developing monoclonal antibodies in immuno-oncology, notably with an anti-VISTA program targeting the same myeloid checkpoint as PharmAbcine's PMC-309. Most directly comparable peer given shared VISTA target and overlapping oncology indications.
- LegoChem Biosciences: Korean biotech developing antibody-based therapeutics including antibody-drug conjugates, with active collaboration agreement with PharmAbcine. Geographic and therapeutic category peer in the Korean biotech ecosystem.
Emerging players
- Aprogen: Korean biotech that licensed PharmAbcine's PMC-309 for further development and commercialization. As a downstream development partner on the same asset, Aprogen occupies an emerging/biopharma space overlapping the same anti-VISTA target.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
PharmAbcine social profiles
Digital presencePharmAbcine compliance and trust
Trust signalCompliance1 record
PharmAbcine financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmAbcine leadership team
Management profileNumber of profiles
Profiles7 records
PharmAbcine subsidiaries and ownership
Company hierarchySubsidiaries2 records
PharmAbcine funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmAbcine M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmAbcine
What does PharmAbcine do?
PharmAbcine is a clinical-stage biotechnology company that discovers and develops fully human therapeutic monoclonal antibodies using its proprietary HuPhage Display platform, with a pipeline targeting cancer, inflammatory diseases, and ophthalmology indications. Its lead candidates include Olinvacimab (anti-VEGFR2), PMC-309 (anti-VISTA), PMC-403 (TIE2-activating), PMC-402, and PMC-005, developed either for direct clinical advancement or for out-licensing to global biopharmaceutical partners.
Is PharmAbcine a public or private company?
PharmAbcine is a public company. It is classified as public and is currently operating.
When was PharmAbcine founded?
PharmAbcine was founded in 2008. It employs 11 to 50 people.
Where is PharmAbcine based?
PharmAbcine is headquartered in Daejeon, South Korea, in the Asia region.
How does PharmAbcine make money?
Two revenue lines are on record. Licensing Revenue is the primary driver. The others are out-licensed PMC-309 to Aprogen.
Who are PharmAbcine's main competitors?
Broad incumbents on record are Genexine, Celltrion, Regeneron Pharmaceuticals and Hanmi Pharmaceutical. Others are WuXi Biologics and Samsung Biologics. Direct peers are Genmab, MacroGenics and LegoChem Biosciences. Aprogen is listed as an emerging player.
Does PharmAbcine have an API?
No public API is recorded for PharmAbcine.